New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
08:22 EDTCGIXCancer Genetics launches genomic test for FL, MCL
Cancer Genetics announced it has received CLIA and New York state approvals for clinical use of its proprietary mature B-cell neoplasm array, or MatBA for Follicular Lymphoma, or MatBA-FL, and Mantle-Cell Lymphoma, or MatBA-MCL. Both tests further extend the portfolio in hematologic cancers being developed by CGI and both were developed and validated via a research collaboration with Memorial Sloan-Kettering Cancer Center. MatBA-FL and MatBA-MCL assist clinicians in the prognosis of Follicular Lymphoma, or FL, and Mantle-Cell Lymphoma, or MCL. MatBA-FL identifies genomic aberrations that are associated with the high frequency of transformation of FL into Diffuse Large B-Cell Lymphoma, or DLBCL, and shorter overall survival, or OS. MatBA-MCL identifies genomic aberrations that are associated with high frequency of either a leukemic involvement and/or shorter OS. Understanding the potential outcome for the patient is critical in making informed choices about treatment selection, clinical trial involvement and patient management.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:45 EDTCGIXCancer Genetics awarded multimillion dollar clinical trial
Cancer Genetics announced that it has been awarded a multimillion dollar, clinical trial in hematological cancers by a leading biotech company the trial is the largest in the company's history of providing clinical trial and genomic services to global biopharma companies. As part of the agreement, CGI will perform all testing, and provide genomic information and monitoring for CLL patients enrolled in multi-arm, randomized, multicenter, global trials. The CLL trials are expected to contribute up to $6.2M in revenue over several years as patients are selected, treated, and monitored using pathway-specific, targeted therapies, and combination therapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use